oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2019-18-6-39-49oncotomsk-1242Research ArticleЛАБОРАТОРНЫЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯLABORATORY AND EXPERIMENTAL STUDIESИНТЕГРАЛЬНЫЙ АНАЛИЗ ГЕНОМНЫХ И ТРАНСКРИПТОМНЫХ ИЗМЕНЕНИЙ ПРИ СВЕТЛОКЛЕТОЧНОЙ ПОЧЕЧНО-КЛЕТОЧНОЙ КАРЦИНОМЕ В РОССИЙСКОЙ ПОПУЛЯЦИИINTEGRAL ANALYSIS OF GENOMIC AND TRANSCRIPTOMIC CHANGES IN CLEAR CELL RENAL CELL CARCINOMA IN THE RUSSIAN POPULATIONhttps://orcid.org/0000-0003-3761-6776СолодскихС. А.SolodskikhS. A.

младший научный сотрудник кафедры генетики, цитологии и биоинженерии

SPIN-код: 5833-6368Россия, г. Воронеж, 394000, Университетская площадь, 1

Junior Researcher

1, Universitetskaya square, 394000, Voronezh, Russia

s.solodskih@gmail.comhttps://orcid.org/0000-0002-4721-3447ПаневинаА. В.PanevinaA. V.

лаборант

SPIN-код: 2356-2166  Россия, г. Воронеж, 394000, Университетская площадь, 1

laboratory assistant

1, Universitetskaya square, 394000, Voronezh, Russia 

НовиковаА. Г.NovikovaA. G.

student

1, Universitetskaya square, 394000, Voronezh, Russia 

https://orcid.org/0000-0002-5820-1804ДворецкаяЮ. Д.DvoretskayaJ. D.https://orcid.org/0000-0003-2076-3868ГрязноваМ. В.GryaznovaM. V.https://orcid.org/0000-0002-1334-4828СтарковА. А.StarkovA. A.

PhD, профессор

AuthorID (РИНЦ): 81262США, г. Нью-Йорк, 1300, Йорк Авеню, 10065

PhD, Professor

1, Universitetskaya square, 394000, Voronezh, Russia 

МасловА. Ю.MaslovA. Yu.

кандидат биологических наук, старший научный сотрудник, профессор

SPIN-код: 9137-3622. AuthorID (РИНЦ): 746138 Россия, г. Воронеж, 394000, Университетская площадь, 1

США, г. Бронкс, 1300, Моррис Парк Авеню, 10461

PhD, Senior Researcher, Professor

1, Universitetskaya square, 394000, Voronezh, Russia 

1300, Morris Park avenue, 10461, Bronx, USA

МихайловА. А.MikhailovA. A.

Россия, 394000, г. Воронеж, ул. Вайцеховского, 4

1, Universitetskaya square, 394000, Voronezh, Russia

 

4, Vaitsekhovskogo street, 394000, Voronezh, Russia

https://orcid.org/0000-0003-0183-4149ХинопулосК.KhinoluposK.

PhD, профессор 

Author ID (Scopus): 6602951392Венгрия, г. Будапешт, 1085, ул. Ульти, 26

 

PhD, Professor

26, ulti street, 1085, Budapest, Hungary

https://orcid.org/0000-0003-1294-8686ПоповВ. Н.PopovV. N.

доктор биологических наук, заведующий кафедрой генетики, цитологии и биоинженерии; ректор

SPIN-код: 7257-5052. AuthorID (РИНЦ): 88213Россия, г. Воронеж, 394000, Университетская площадь, 1

Россия, г. Воронеж, 394000, просп. Революции, 19

DSc, Head of the Department of Genetics, Cytology and Bioengineering

1, Universitetskaya square, 394000, Voronezh, Russia 

19, Prospect Revolution, 394000, Voronezh, Russia

ФГБОУ ВО «Воронежский государственный университет»РоссияVoronezh State UniversityRussian FederationКолледж Уэилл Медикал Корнеллского университетаСоединённые Штаты АмерикиCornell University Weill Medical CollegeUnited StatesФГБОУ ВО «Воронежский государственный университет», Медицинский колледж им. Альберта ЭйнштейнаРоссияVoronezh State University, College of Medicine Albert EinsteinRussian FederationФГБОУ ВО «Воронежский государственный университет», БУЗ ВО «Воронежский областной клинический онкологический диспансер»РоссияVoronezh State University, Voronezh Regional Clinical Oncology CenterRussian FederationУниверситет ЗеммельвайсаВенгрияSemmelweis UniversityHungaryФГБОУ ВО «Воронежский государственный университет», ФГБОУ ВО «Воронежский государственный университет инженерных технологий»РоссияVoronezh State UniversityRussian Federation2019040120201863949Copyright © Солодских С.А., Паневина А.В., Новикова А.Г., Дворецкая Ю.Д., Грязнова М.В., Старков А.А., Маслов А.Ю., Михайлов А.А., Хинопулос К., Попов В.Н., 20202020Солодских С.А., Паневина А.В., Новикова А.Г., Дворецкая Ю.Д., Грязнова М.В., Старков А.А., Маслов А.Ю., Михайлов А.А., Хинопулос К., Попов В.Н.Solodskikh S.A., Panevina A.V., Novikova A.G., Dvoretskaya J.D., Gryaznova M.V., Starkov A.A., Maslov A.Y., Mikhailov A.A., Khinolupos K., Popov V.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1242ракмикроматрицымутациигеномтранскриптомпочечно-клеточная карциномарак почкиcancermicroarraysmutationsgenometranscriptrenal cell carcinomakidney cancerРабота выполнена при поддержке гранта Министерства науки и высшего образования Российской Федерации 14.586.21.0062 (уникальный идентификатор договора RFMEFI58618X0062) (В.Н. Попов).This study was financially supported by the grant of the Ministry of Science and Higher Education of the Russian Federation 14.586.21.0062 (unique contract identifier RFMEFI58618X0062) (V.N. Popov).ReferencesBray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424. doi:10.3322/caac.21492.Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424. doi:10.3322/caac.21492.Bazzi W.M., Sjoberg D.D., Feuerstein M.A., Maschino A., Verma S., Bernstein M., O’Brien M.F., Jang T., Lowrance W., Motzer R.J., Russo P. Long-Term Survival Rates after Resection for Locally Advanced Kidney Cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 Experience. J Urol. 2015 Jun; 193(6): 1911–6. doi: 10.1016/j.juro.2014.12.022.Bazzi W.M., Sjoberg D.D., Feuerstein M.A., Maschino A., Verma S., Bernstein M., O’Brien M.F., Jang T., Lowrance W., Motzer R.J., Russo P. Long-Term Survival Rates after Resection for Locally Advanced Kidney Cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 Experience. J Urol. 2015 Jun; 193(6): 1911–6. doi: 10.1016/j.juro.2014.12.022.Wu X., Shu X. Epidemiology of Renal Cell Carcinoma. Renal Cell Carcinoma. Tokyo: Springer Japan; 2017: 1–18. doi: 10.1007/978-4-431-55531-5_1.Wu X., Shu X. Epidemiology of Renal Cell Carcinoma. Renal Cell Carcinoma. Tokyo: Springer Japan; 2017: 1–18. doi: 10.1007/978-4-431-55531-5_1.Cheville J.C., Lohse C.M., Zincke H., Weaver A.L., Blute M.L. Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma. Am J Surg Pathol. 2003; 27(5): 612–624. doi: 10.1097/00000478-200305000-00005.Cheville J.C., Lohse C.M., Zincke H., Weaver A.L., Blute M.L. Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma. Am J Surg Pathol. 2003; 27(5): 612–624. doi: 10.1097/00000478-200305000-00005.Kume H., Takahashi S., Teramoto S., Isurugi K. Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. BJU Int. 2001; 88(7): 804–804. doi: 10.1046/j.1464-410-X.2001.2505b.x.Kume H., Takahashi S., Teramoto S., Isurugi K. Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. BJU Int. 2001; 88(7): 804–804. doi: 10.1046/j.1464-410-X.2001.2505b.x.Choueiri T.K., Je Y., Cho E. Analgesic use and the risk of kidney cancer: A meta-analysis of epidemiologic studies. Int J Cancer. 2014 Jan 15; 134(2): 384–96. doi: 10.1002/ijc.28093.Choueiri T.K., Je Y., Cho E. Analgesic use and the risk of kidney cancer: A meta-analysis of epidemiologic studies. Int J Cancer. 2014 Jan 15; 134(2): 384–96. doi: 10.1002/ijc.28093.Ridge C., Pua B., Madoff D. Epidemiology and Staging of Renal Cell Carcinoma. Semin Intervent Radiol. 2014; 31(01): 003–008. doi:10.1055/s-0033-1363837.Ridge C., Pua B., Madoff D. Epidemiology and Staging of Renal Cell Carcinoma. Semin Intervent Radiol. 2014; 31(01): 003–008. doi:10.1055/s-0033-1363837.Moch H., Cubilla A.L., Humphrey P.A., Reuter V.E., Ulbright T.M. WHO classification of tumours of the urinary system and male genital organs. Eur Urol. 2016 Jul; 70(1): 93–105. doi: 10.1016/j.eururo.2016.02.029.Moch H., Cubilla A.L., Humphrey P.A., Reuter V.E., Ulbright T.M. WHO classification of tumours of the urinary system and male genital organs. Eur Urol. 2016 Jul; 70(1): 93–105. doi: 10.1016/j.eururo.2016.02.029.Gossage L., Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol. 2010 May; 7(5): 277–88. doi: 10.1038/nrclinonc.2010.42.Gossage L., Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol. 2010 May; 7(5): 277–88. doi: 10.1038/nrclinonc.2010.42.Cheng L., Zhang S., MacLennan G.T., Lopez-Beltran A., Montironi R. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol. 2009; 40(1): 10–29. doi: 10.1016/j.humpath.2008.09.009.Cheng L., Zhang S., MacLennan G.T., Lopez-Beltran A., Montironi R. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol. 2009; 40(1): 10–29. doi: 10.1016/j.humpath.2008.09.009.Ricketts C.J., De Cubas A.A., Fan H., Smith C.C., Lang M., Reznik E., Bowlby R., Gibb E.A., Akbani R., Beroukhim R., Bottaro D.P., Choueiri T.K., Gibbs R.A., Godwin A.K., Haake S., Hakimi A.A., Henske E.P., Hsieh J.J., Ho T.H., Kanchi R.S., Krishnan B., Kwiatkowski D.J., Lui W., Merino M.J., Mills G.B., Myers J., Nickerson M.L., Reuter V.E., Schmidt L.S., Shelley C.S., Shen H., Shuch B., Signoretti S., Srinivasan R., Tamboli P., Thomas G., Vincent B.G., Vocke C.D., Wheeler D.A., Yang L., Kim W.Y., Robertson A.G.; Cancer Genome Atlas Research Network, Spellman P.T., Rathmell W.K., Linehan W.M. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 Jun 19; 23(12): 3698. doi: 10.1016/j.celrep.2018.06.032.Ricketts C.J., De Cubas A.A., Fan H., Smith C.C., Lang M., Reznik E., Bowlby R., Gibb E.A., Akbani R., Beroukhim R., Bottaro D.P., Choueiri T.K., Gibbs R.A., Godwin A.K., Haake S., Hakimi A.A., Henske E.P., Hsieh J.J., Ho T.H., Kanchi R.S., Krishnan B., Kwiatkowski D.J., Lui W., Merino M.J., Mills G.B., Myers J., Nickerson M.L., Reuter V.E., Schmidt L.S., Shelley C.S., Shen H., Shuch B., Signoretti S., Srinivasan R., Tamboli P., Thomas G., Vincent B.G., Vocke C.D., Wheeler D.A., Yang L., Kim W.Y., Robertson A.G.; Cancer Genome Atlas Research Network, Spellman P.T., Rathmell W.K., Linehan W.M. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 Jun 19; 23(12): 3698. doi: 10.1016/j.celrep.2018.06.032.Sato Y., Yoshizato T., Shiraishi Y., Maekawa S., Okuno Y., Kamura T., Shimamura T., Sato-Otsubo A., Nagae G., Suzuki H., Nagata Y., Yoshida K., Kon A., Suzuki Y., Chiba K., Tanaka H., Niida A., Fujimoto A., Tsunoda T., Morikawa T., Maeda D., Kume H., Sugano S., Fukayama M., Aburatani H., Sanada M., Miyano S., Homma Y., Ogawa S. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013 Aug; 45(8): 860–7. doi: 10.1038/ng.2699.Sato Y., Yoshizato T., Shiraishi Y., Maekawa S., Okuno Y., Kamura T., Shimamura T., Sato-Otsubo A., Nagae G., Suzuki H., Nagata Y., Yoshida K., Kon A., Suzuki Y., Chiba K., Tanaka H., Niida A., Fujimoto A., Tsunoda T., Morikawa T., Maeda D., Kume H., Sugano S., Fukayama M., Aburatani H., Sanada M., Miyano S., Homma Y., Ogawa S. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013 Aug; 45(8): 860–7. doi: 10.1038/ng.2699.Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T., O’Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., Tukiainen T., Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016 Aug 18; 536(7616): 285–91. doi: 10.1038/nature19057.Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T., O’Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., Tukiainen T., Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016 Aug 18; 536(7616): 285–91. doi: 10.1038/nature19057.McLaren W., Gil L., Hunt S.E., Riat H.S., Ritchie G.R., Thormann A., Flicek P., Cunningham F. The Ensembl Variant Effect Predictor. Genome Biol. 2016 Jun 6; 17(1): 122. doi: 10.1186/s13059-016-0974-4.McLaren W., Gil L., Hunt S.E., Riat H.S., Ritchie G.R., Thormann A., Flicek P., Cunningham F. The Ensembl Variant Effect Predictor. Genome Biol. 2016 Jun 6; 17(1): 122. doi: 10.1186/s13059-016-0974-4.Danecek P., Auton A., Abecasis G., Albers C.A., Banks E., DePris-to M.A., Handsaker R.E., Lunter G., Marth G.T., Sherry S.T., McVean G., Durbin R.; 1000 Genomes Project Analysis Group. The variant call format and VCFtools. Bioinformatics. 2011; 27(15): 2156–8. doi: 10.1093/bioinformatics/btr330.Danecek P., Auton A., Abecasis G., Albers C.A., Banks E., DePris-to M.A., Handsaker R.E., Lunter G., Marth G.T., Sherry S.T., McVean G., Durbin R.; 1000 Genomes Project Analysis Group. The variant call format and VCFtools. Bioinformatics. 2011; 27(15): 2156–8. doi: 10.1093/bioinformatics/btr330.Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., Mueller R., Nolan T., Pfaffl M.W., Shipley G.L., Vandesompele J., Wittwer C.T. The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. Clin Chem. 2009 Apr; 55(4): 611–22. doi: 10.1373/clinchem.2008.112797.Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., Mueller R., Nolan T., Pfaffl M.W., Shipley G.L., Vandesompele J., Wittwer C.T. The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. Clin Chem. 2009 Apr; 55(4): 611–22. doi: 10.1373/clinchem.2008.112797.Charlesworth B. Population Genetics. Encyclopedia of Biodiversity. Elsevier; 2013: 182–198. doi:10.1016/B978-0-12-384719-5.00116-7.Charlesworth B. Population Genetics. Encyclopedia of Biodiversity. Elsevier; 2013: 182–198. doi:10.1016/B978-0-12-384719-5.00116-7.Solodskikh S.A., Panevina A.V., Gryaznova M.V., Gureev A.P., Serzhantova O.V., Mikhailov A.A., Maslov A.Y., Popov V.N. Targeted sequencing to discover germline variants in the BRCA1 and BRCA2 genes in a Russian population and their association with breast cancer risk. Mutat Res. 2019 Jan; 813: 51–57. doi: 10.1016/j.mrfmmm.2018.12.005.Solodskikh S.A., Panevina A.V., Gryaznova M.V., Gureev A.P., Serzhantova O.V., Mikhailov A.A., Maslov A.Y., Popov V.N. Targeted sequencing to discover germline variants in the BRCA1 and BRCA2 genes in a Russian population and their association with breast cancer risk. Mutat Res. 2019 Jan; 813: 51–57. doi: 10.1016/j.mrfmmm.2018.12.005.Brugarolas J. Molecular Genetics of Clear-Cell Renal Cell Carcinoma. J Clin Oncol. 2014 Jun 20; 32(18): 1968–76. doi: 10.1200/JCO.2012.45.2003.Brugarolas J. Molecular Genetics of Clear-Cell Renal Cell Carcinoma. J Clin Oncol. 2014 Jun 20; 32(18): 1968–76. doi: 10.1200/JCO.2012.45.2003.Serasanambati M., Chilakapati S.R. Function of Nuclear Factor Kappa B (NF-kB) in Human Diseases-A Review. South Indian J Biol Sci. 2016; 2(4): 368. doi: 10.22205/sijbs/2016/v2/i4/103443.Serasanambati M., Chilakapati S.R. Function of Nuclear Factor Kappa B (NF-kB) in Human Diseases-A Review. South Indian J Biol Sci. 2016; 2(4): 368. doi: 10.22205/sijbs/2016/v2/i4/103443.Iqbal N., Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014; 2014: 852748. doi: 10.1155/2014/852748.Iqbal N., Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014; 2014: 852748. doi: 10.1155/2014/852748.Krishnamurti U., Silverman J.F. HER2 in Breast Cancer. Adv Anat Pathol. 2014 Mar; 21(2): 100–7. doi: 10.1097/PAP.0000000000000015.Krishnamurti U., Silverman J.F. HER2 in Breast Cancer. Adv Anat Pathol. 2014 Mar; 21(2): 100–7. doi: 10.1097/PAP.0000000000000015.Kümler I., Tuxen M.K., Nielsen D.L. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev. 2014 Mar; 40(2): 259–70. doi: 10.1016/j.ctrv.2013.09.002.Kümler I., Tuxen M.K., Nielsen D.L. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev. 2014 Mar; 40(2): 259–70. doi: 10.1016/j.ctrv.2013.09.002.Bronchud M.H., Castillo S., Escriva de Romaní S., Mourelo S., Fernández A., Baena C., Murillo J., Julia J.C., Esquius J., Romero R., Andreu X. HER2 Blockade in Metastatic Collecting Duct Carcinoma (CDC) of the Kidney: A Case Report. Onkologie. 2012; 35(12): 776–9. doi: 10.1159/000345041.Bronchud M.H., Castillo S., Escriva de Romaní S., Mourelo S., Fernández A., Baena C., Murillo J., Julia J.C., Esquius J., Romero R., Andreu X. HER2 Blockade in Metastatic Collecting Duct Carcinoma (CDC) of the Kidney: A Case Report. Onkologie. 2012; 35(12): 776–9. doi: 10.1159/000345041.Shen C., Kaelin W.G. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013 Feb; 23(1): 18–25. doi: 10.1016/j.semcancer.2012.06.001.Shen C., Kaelin W.G. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013 Feb; 23(1): 18–25. doi: 10.1016/j.semcancer.2012.06.001.

The authors declare that there are no conflicts of interest present.